Skip to main content
OpenTrials
Completed

NCT Number: NCT04730336

Assessing the Impact of Tixel Treatment of Periorbital Wrinkles on Dry Eye Symptoms and Signs

Pilot study where effect of standard Tixel treatment as used for periorbital wrinkles would be assessed on Dry Eye Disease symptoms and signs

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Midland Eye

Solihull, B91 2AW, United Kingdom

About this study

Safety Assessment will be asses via AE/SAE reporting and Impact Assessment of the effect of treatment on dry eye symptoms and signs through multiple test indicate Dry Eye

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Mild to Moderate Periorbital wrinkles
  • OSDI score of at least 23
  • Noninvasive Tear film break up time (NIKBUT) ≤ 10 seconds
  • No other eye or skin or immune problems
  • Willing and able to provide written informed consent.
  • Willing to participate in all study activities and instructions.

Exclusion criteria

  • Pregnancy and/or breastfeeding
  • Lesions in the periorbital area
  • Acute severe blepharitis
  • Acute conjunctivitis
  • Other concomitant anterior eye disease
  • Has undergone outdoors/sunbed tanning during the last 4 weeks
  • Is unwilling to follow the Tixel aftercare instructions after each of the three Tixel treatments.
  • Active Herpes Simplex or tendency for Herpes Simplex in the periorbital area (meaning the subject has had the condition previously).
  • Current skin cancer, malignant sites and/or advanced premalignant lesions or moles in the treatment area.
  • An impaired immune system condition or use of immunosuppressive medication.
  • Collagen disorders, keloid formation and/or abnormal wound healing.
  • Previous invasive/ablative procedures in the areas to be treated within 3 months prior to initial treatment or plans for such treatment during the course of the Tixel2 device treatment, or before complete healing of such treatments has occurred.
  • Any patient who takes or has taken any medications (including via topical application), herbal treatment (oral or topic), food supplements or vitamins, which may cause fragile skin or impaired skin healing during the last 3 months.
  • Any patient who has used oral Isotretinoin (Accutane® or Roaccutan®) within 3 months prior to treatment or less.
  • Any patient who has a history of bleeding coagulopathies or use of anticoagulants.
  • Any patient who has tattoos or permanent makeup in the treated area.
  • Any patient who has burned skin, blistered skin, irritated skin, or sensitive skin in any of the areas to be treated.
  • Any patient who underwent thread lifting of the area to be treated in the last 3 months.

Treatment and study plan

Tixel

Device

Peri-Orbital fractional treatment on the Eye-Lid to assess the effect on Dry Eye symptoms

Other names: Fractional

Primary outcomes

  1. NIBUT in Seconds

    Time frame: 18 Weeks

    Non-Invasive Break Up Time

  2. Ocular Surface Disease Index questionnaire

    Time frame: 18 Weeks

    Total 12 questions will be asked, ranked between 0-100. 0 being no dry eye symptoms and 100 severe dry eye symptoms.

  3. SAFETY, number of AEs

    Time frame: 18 Weeks

    Any safety related event during the study will be recorded and analyzed

Secondary outcomes

  1. Topography mm D

    Time frame: 18 Weeks

    Topography with K readings

  2. Slit Lamp Exam; Normal, Abnormal

    Time frame: 18 Weeks

    Multiple Slit Lamp tests

  3. Standardized Patient Evaluation of Eye Dryness (SPEED) Questionnaire

    Time frame: 18 Weeks

    Assessment of the frequency and severity of dry eye symptoms. scored 0 to 28; 0 being no dry eye symptoms and 28 severe dry eye symptoms.

  4. Lid margin profile

    Time frame: 18 Weeks

    Lid margin profile

  5. Tear Sampling Analysis

    Time frame: 18 Weeks

    ocular tear biomarkers

  6. Staining; Total Ocular Staining Score

    Time frame: 18 Weeks

    Corneal staining fluorescein and conjunctival/lid margin staining lissamine green

Sponsors and collaborators

Lead sponsor

Aston University

Other

Registry information

Official study title

Assessment of the Impact of Tixel Treatment of Periorbital Wrinkles on Dry Eye Symptoms and Signs in Patients With Dry Eye

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Jan 29, 2021
Registry last updated
Mar 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.